We are live on ! Find out more
EC

Euclidean Capital Portfolio holdings

AUM $392M
1-Year Est. Return 31.85%
This Fund
S&P 500
This Quarter Est. Return
+65.84%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$472M
AUM Growth
–
Cap. Flow
+$346M
Cap. Flow %
73.25%
Top 10 Hldgs %
100%
Holding
10
New
10
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PMVP icon
PMV Pharmaceuticals
PMVP
+$164M
2
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$45.6M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$40.2M
4
FHTX icon
Foghorn Therapeutics
FHTX
+$24.2M
5
RAPT
RAPT Therapeutics
RAPT
+$20M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.36%
2 Financials 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$59.2M
$257M 54.42%
+4,179,416
New +$164M
NGM
2
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$63.1M 13.37%
+2,083,602
New +$45.6M
ORIC icon
3
Oric Pharmaceuticals
ORIC
$1.15B
$47.4M 10.04%
+1,400,435
New +$40.2M
DNLI icon
4
Denali Therapeutics
DNLI
$3.65B
$27.1M 5.74%
+323,749
New +$19.6M
FHTX icon
5
Foghorn Therapeutics
FHTX
$266M
$25.6M 5.41%
+1,261,261
New +$24.2M
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$16M 3.38%
+554,325
New +$14M
ALEC icon
7
Alector
ALEC
$168M
$14.8M 3.14%
+980,894
New +$12.2M
RAPT
8
DELISTED
RAPT Therapeutics
RAPT
$14.5M 3.08%
+91,975
New +$20M
RVMD icon
9
Revolution Medicines
RVMD
$39.9B
$3.7M 0.78%
+93,436
New +$3.69M
FFBC icon
10
First Financial Bancorp
FFBC
$3.55B
$3.04M 0.64%
+173,576
New +$2.72M

Similar funds

WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
RC
Riposte Capital New York $392M AUM 69.08% 1-Year Est. Return
DCM
Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
BWM
Buckley Wealth Management Las Vegas, Nevada $392M AUM 28.21% 1-Year Est. Return
IPW
Inlet Private Wealth Jupiter, Florida $392M AUM 25.74% 1-Year Est. Return
TCM
Turas Capital Management Boston, Massachusetts $392M AUM
MA
Mezzasalma Advisors Tinton Falls, New Jersey $391M AUM 40.85% 1-Year Est. Return

Euclidean Capital's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Euclidean Capital, which disclosed 10 positions worth $472M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is PMV Pharmaceuticals: 4,179,416 shares worth $257M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, followed by Financials.

  • Euclidean Capital's largest Q4 2020 buy was PMV Pharmaceuticals: 4,179,416 shares worth $257M.
  • Euclidean Capital's ten largest holdings make up 100% of its $472M portfolio in Q4 2020.
  • Euclidean Capital disclosed 10 positions in Q4 2020, its first 13F filing on record.

Based on Euclidean Capital's 13F filing for Q4 2020, filed 12 Feb 2021.